A Phase II Study Of Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 18 Dec 2018
At a glance
- Drugs Fludarabine (Primary) ; Ibrutinib (Primary) ; Pembrolizumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 12 Jun 2018 Planned End Date changed from 30 Mar 2027 to 31 Dec 2030.
- 12 Jun 2018 Planned primary completion date changed from 30 Mar 2027 to 31 Dec 2027.